Free Trial

BioNexus Gene Lab (BGLC) Competitors

BioNexus Gene Lab logo
$4.90 +0.02 (+0.41%)
Closing price 04:00 PM Eastern
Extended Trading
$4.93 +0.03 (+0.61%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BGLC vs. CCM, MRAI, BRTX, MGRX, SSY, VSEE, ATIP, DHAC, ACON, and NIVF

Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Concord Medical Services (CCM), Marpai (MRAI), Biorestorative Therapies (BRTX), Mangoceuticals (MGRX), SunLink Health Systems (SSY), VSee Health (VSEE), ATI Physical Therapy (ATIP), Digital Health Acquisition (DHAC), Aclarion (ACON), and NewGenIvf Group (NIVF). These companies are all part of the "healthcare" industry.

BioNexus Gene Lab vs. Its Competitors

Concord Medical Services (NYSE:CCM) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

In the previous week, Concord Medical Services had 7 more articles in the media than BioNexus Gene Lab. MarketBeat recorded 8 mentions for Concord Medical Services and 1 mentions for BioNexus Gene Lab. BioNexus Gene Lab's average media sentiment score of 1.87 beat Concord Medical Services' score of -0.06 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company Overall Sentiment
Concord Medical Services Neutral
BioNexus Gene Lab Very Positive

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 46.5% of Concord Medical Services shares are owned by company insiders. Comparatively, 0.7% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Concord Medical Services has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -22.85%. Concord Medical Services' return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
Concord Medical ServicesN/A N/A N/A
BioNexus Gene Lab -22.85%-24.18%-20.14%

BioNexus Gene Lab has lower revenue, but higher earnings than Concord Medical Services.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concord Medical Services$52.60M0.45-$42.23MN/AN/A
BioNexus Gene Lab$9.27M0.95-$1.60MN/AN/A

Concord Medical Services has a beta of -0.9, suggesting that its stock price is 190% less volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 5.08, suggesting that its stock price is 408% more volatile than the S&P 500.

Summary

Concord Medical Services beats BioNexus Gene Lab on 6 of the 11 factors compared between the two stocks.

Get BioNexus Gene Lab News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGLC vs. The Competition

MetricBioNexus Gene LabMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$8.77M$7.30B$5.70B$9.51B
Dividend YieldN/A2.84%4.69%4.01%
P/E RatioN/A15.7721.1920.14
Price / Sales0.9542.18461.30104.37
Price / CashN/A26.7436.2258.56
Price / Book1.069.718.665.87
Net Income-$1.60M$239.96M$3.25B$258.55M
7 Day Performance-3.92%2.92%4.20%2.23%
1 Month Performance87.02%6.14%10.82%12.76%
1 Year Performance-2.99%17.27%34.70%19.36%

BioNexus Gene Lab Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BGLC
BioNexus Gene Lab
1.2014 of 5 stars
$4.90
+0.4%
N/A-4.1%$8.77M$9.27M0.0030Positive News
CCM
Concord Medical Services
1.0849 of 5 stars
$5.31
+1.6%
N/A-19.3%$23.03M$52.60M0.00970Gap Down
MRAI
Marpai
N/A$1.37
+1.5%
N/A+116.1%$22.65M$34.87M-0.52150News Coverage
BRTX
Biorestorative Therapies
3.8083 of 5 stars
$1.53
-4.7%
$18.00
+1,080.3%
-3.8%$11.44M$400K-1.047Positive News
MGRX
Mangoceuticals
0.9776 of 5 stars
$1.47
-3.3%
N/A-98.1%$7.60M$511.08K-0.323
SSY
SunLink Health Systems
2.5538 of 5 stars
$1.00
+3.2%
N/A+55.2%$7.05M$31.09M7.151,376News Coverage
Dividend Announcement
VSEE
VSee Health
1.0839 of 5 stars
$1.32
-4.3%
$5.00
+278.8%
-56.1%$4.75MN/A0.00N/AGap Down
ATIP
ATI Physical Therapy
N/A$1.03
flat
N/A-94.2%$4.54M$741.86M-0.065,600
DHAC
Digital Health Acquisition
N/A$1.22
+3.4%
N/A-62.8%$4.40MN/A0.002,021
ACON
Aclarion
2.9896 of 5 stars
$7.34
+0.1%
$11,758.50
+160,097.5%
-99.7%$4.27M$54.60K0.007Gap Down
NIVF
NewGenIvf Group
N/A$0.59
-7.3%
N/A-99.7%$2.54M$5.43M0.00N/APositive News

Related Companies and Tools


This page (NASDAQ:BGLC) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners